SCHEMBL2197489

SCHEMBL2197489

Cc1ccc(C(=O)O)cc1C(=O)c1ccc(Nc2ccc(Br)cc2[N+](=O)[O-])cc1Cl

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 6/20 0.60
MEN1 O00255 5/20 0.60
MAPK13 O15264 5/20 0.59
MAPK12 P53778 5/20 0.59
MAPK11 Q15759 5/20 0.59
MAPK14 Q16539 5/20 0.59
MAPT P10636 3/20 0.48
LMNA P02545 2/20 0.48
ALDH1A1 P00352 1/20 0.48
ATM Q13315 1/20 0.48
SMN1; SMN2 Q16637 1/20 0.48
HCAR3 P49019 2/20 0.48
HPGD P15428 2/20 0.46
AKR1C3 P42330 2/20 0.46
AKR1C2 P52895 2/20 0.46
GAA P10253 1/20 0.46
POLB P06746 1/20 0.46
AKR1B10 O60218 1/20 0.44
AKR1B1 P15121 1/20 0.44
AKR1C4 P17516 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2199762 0.91 MAPK13 (0.57) KMT2AMEN1MAPK13MAPK12MAPK11
SCHEMBL7210815 0.89 MAPK13 (0.62) KMT2AMEN1MAPK13MAPK12MAPK11
SCHEMBL7195483 0.89 MAPK13 (0.61) KMT2AMEN1MAPK13MAPK12MAPK11
SCHEMBL2199203 0.87 MAPK13 (0.77) KMT2AMEN1MAPK13MAPK12MAPK11
SCHEMBL2200138 0.87 MAPK13 (0.60) KMT2AMEN1MAPK13MAPK12MAPK11
SCHEMBL2197537 0.87 MAPK13 (0.53) KMT2AMEN1MAPK13MAPK12MAPK11
SCHEMBL7196080 0.86 MAPK13 (0.63) KMT2AMEN1MAPK13MAPK12MAPK11
SCHEMBL7198829 0.86 MAPK14 (0.79) KMT2AMEN1MAPK13MAPK12MAPK11
SCHEMBL7198676 0.85 MAPK13 (0.61) KMT2AMEN1MAPK13MAPK12MAPK11
SCHEMBL2197842 0.84 MAPK14 (0.79) KMT2AMEN1MAPK13MAPK12MAPK11

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1658263-B9 NOVEL AMINOBENZOPHENONE COMPOUNDS LEO PHARMA AS (DK) 2011-11-09 EP disclosed
US-7977387-B2 Aminobenzophenone compounds LEO PHARMA A/S (DK) 2011-07-12 US disclosed
EP-1658263-B1 NOVEL AMINOBENZOPHENONE COMPOUNDS LEO PHARMA AS (DK) 2010-06-02 EP disclosed
US-20060166990-A1 Novel aminobenzophenone compounds LEO PHARMA A/S (DK) 2006-07-27 US disclosed
EP-1658263-A1 NOVEL AMINOBENZOPHENONE COMPOUNDS Leo Pharma A/S (DK) 2006-05-24 EP disclosed
WO-2005009940-A1 NOVEL AMINOBENZOPHENONE COMPOUNDS LEO PHARMA A/S (DK) 2005-02-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060166990-A1 Novel aminobenzophenone compounds NFKBIA, UACA, ALDH7A1 KMT2A 3430/4885MEN1 1114/4885MAPK13 1063/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.